




MEMORANDUM

TO: University Deans, Chairs, Faculty, & Staff

FROM: Selwyn M. Vickers, MD, *Senior Vice President for Medicine and Dean, School of* 
Medicine

Christopher S. Brown, PhD, *Vice President for Research* 

Robert P. Kimberly, MD, *Senior Associate Dean for Clinical and Translational Research* 

DATE: October 1, 2019

SUBJECT: Study Management Fee for Industry-Funded Clinical Trial Budgets

All industry-funded clinical trial budgets are assessed a non-refundable Study Management Fee of \$5,500.

This Study Management Fee subsumes the UAB Human Subjects Review Fee previously assessed for industry-initiated and sponsored protocols and reflects the costs associated with supporting operations related to the conduct of clinical trials on campus. These operations include:

- Review for the Protection of Human Subjects (IRB)
- Review of Financial Interests by Responsible Personnel (CIRB)
- Medicare Coverage Analysis (CBR)
- Study Management Software (OnCore/PowerTrials)

After the initial year of each study, an annual CTMS Fee of \$1,000 and IRB/CIRB of \$500 will be assessed. Additionally, an IRB/CIRB Fee of \$150 will be assessed at the close-out of trials. These fees will be used to support ongoing operations of these respective units (OnCore/PowerTrials, IRB, and CIRB).

If you have any questions, you may contact Mark Marchant, Director of the Clinical Trials Administrative Office, at 205-934-2098 or marchant@uab.edu.